Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA4 | P22748 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452003 | 1.00 | HCAR2 (0.38) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13843805 | 0.87 | MASP2 (0.38) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18755136 | 0.82 | GLA (0.38) | KDM4EMEN1ALDH1A1LMNAAPP | |
| SCHEMBL22779641 | 0.82 | CCNC (0.31) | — | |
| SCHEMBL16844231 | 0.79 | HDAC1 (0.33) | HDAC3HDAC4HDAC1HDAC2HDAC10 | |
| SCHEMBL13450124 | 0.79 | MAPT (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15364319 | 0.78 | CA12 (0.42) | HCAR2CA1CA2CA12CA7 | |
| SCHEMBL18601687 | 0.78 | MAPT (0.46) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18648890 | 0.78 | CYP2C9 (0.59) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8072668 | 0.77 | KMT2A (0.35) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066417-A9 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-02-27 | — | — | US | claimed |
| US-20240218016-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | claimed |
| US-20240182520-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | ENLITISA SHANGHAI PHARMACEUTICAL CO LTD (CN) | 2024-06-06 | — | — | US | claimed |
| US-20240165247-A1 | NEW PEPTIDE CONJUGATES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-05-23 | — | — | US | claimed |
| US-20240124521-A1 | NEW PEPTIDES | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | claimed |
| CN-117425498-A | Novel peptide conjugates | 艾缇亚(上海)制药有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-117396491-A | Novel peptide-based diagnostic and therapeutic agents | 艾缇亚(上海)制药有限公司 | 2024-01-12 | — | — | CN | claimed |
| US-20230331792-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-10-19 | — | — | US | claimed |
| US-20230113836-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-04-13 | — | — | US | claimed |
| CN-114929283-A | Novel conjugates of peptides and polysaccharides | 艾缇亚(上海)制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| WO-2010037045-A1 | MULTI-ARMED CATECHOL COMPOUND BLENDS | NERITES CORPORATION (US) | 2010-04-01 | — | — | WO | claimed |
| WO-2009113711-A1 | METHOD FOR PRODUCING -MERCAPTO CARBOXYLIC ACIDS | SHOWA DENKO K.K. (JP) | 2009-09-17 | — | — | WO | claimed |
| EP-1568283-B1 | METHOD OF INHIBITING ACRYLAMIDE FORMATION AND USE THEREOF | HAYASHIBARA BIOCHEM LAB (JP) | 2009-08-26 | — | — | EP | claimed |
| US-20060194743-A1 | Method for inhibiting acrylamide formation and use thereof | OKU KAZUYUKI | 2006-08-31 | — | — | US | claimed |
| EP-1568283-A1 | METHOD OF INHIBITING ACRYLAMIDE FORMATION AND USE THEREOF | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2005-08-31 | — | — | EP | claimed |
| EP-1113790-B1 | USE OF A CINNAMIC ACID DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING OR TREATING ELEVATED BLOOD LIPID LEVEL-RELATED DISEASES | KOREA RES INST OF BIOSCIENCE (KR) | 2004-04-21 | — | — | EP | claimed |
| EP-0168277-B1 | Poly(orthoester)polymers containing pendant acid functionalities and labile backbone bonds | MERCK & CO. INC. (US) | 1990-08-01 | — | — | EP | claimed |
| US-4639366-A | Polymers containing pendant acid functionalities and labile backbone bonds | MERCK & CO., INC. (US) | 1987-01-27 | — | — | US | claimed |
| EP-0168277-A1 | Poly(orthoester)polymers containing pendant acid functionalities and labile backbone bonds | MERCK & CO. INC. (US) | 1986-01-15 | — | — | EP | claimed |
| US-4145255-A | ENZYMATIC OXIDATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 1979-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113836-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | DSG1, HBG1, IDUA | HCAR2 1909/4885HDAC3 3907/4885HDAC4 2690/4885 |
| US-20250066417-A9 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | NGLY1, YBX1, VIP | HCAR2 4342/4885HDAC3 4674/4885HDAC4 4394/4885 |
| US-20230331792-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | VIP, MLX, IAPP | HCAR2 4680/4885HDAC3 4331/4885HDAC4 3660/4885 |
| US-20240218016-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | VIP, ARGLU1, NGLY1 | HCAR2 2264/4885HDAC3 4032/4885HDAC4 4250/4885 |
| US-20240182520-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | NGLY1, YBX1, VIP | HCAR2 4342/4885HDAC3 4674/4885HDAC4 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.